Intellia’s $670M cash reserve fuels HAE drug progress despite FDA setback
Intellia Therapeutics, a biotechnology company, has a substantial cash app reserve of approximately $670 million, ensuring its financial stability until mid-2027. Meanwhile, the company faces a setback with its ATTR treatment program, Nexiguran ziclumeran, due to a clinical hold by the FDA.
Intellia is forging ahead with its late-stage candidate lonvoguran ziclumeran (lonvo-z) for treating hereditary angioedema (HAE). The Phase III HAELO study enrollment was completed in September, marking a significant milestone in the drug's development. This progress comes despite the company withdrawing its milestone guidance for Nexiguran ziclumeran (nex-z) due to the FDA's clinical hold on its Phase III trials for treating transthyretin amyloidosis (ATTR).
The net loss for Intellia Therapeutics in the third quarter of 2025 was $101.3 million. Despite this, the company's robust money position indicates its ability to continue investing in its pipeline and operations.
Intellia Therapeutics maintains a strong financial footing with its substantial cash app reserves. While facing challenges with its ATTR treatment program, the company continues to advance its lonvoguran ziclumeran for HAE, with the Phase III HAELO study fully enrolled. The company's financial health and progress in its pipeline will be closely watched as it navigates the regulatory landscape.
